Recombinant Human BTNL9 Fc Chimera Protein, CF Summary
Product Specifications
| Human BTNL9 (Ser35-Lys256) Accession # Q6UXG8-1 | IEGRMD | Human IgG1 (Pro100-Lys330) |
| N-terminus | C-terminus | |
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
9659-BT
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution | Reconstitute at 200 μg/mL in PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
View Larger
Recombinant Human BTNL9 Fc Chimera (Catalog # 9659-BT) inhibits IFN-gamma secretion by human peripheral blood mononuclear cells in the presence of anti-CD3 antibody. The ED50 for this effect is 3-15 μg/mL.
Reconstitution Calculator
Background: BTNL9
Butyrophilin-like 9 (BTNL9) is a member of the BTN/MOG Ig-superfamily and functions as a negative regulator of immune cell activation (1). Human BTNL9 is a 535 amino acid (aa) type I transmembrane glycoprotein that contains a 222 aa extracellular domain (ECD), a 21 aa helical transmembrane domain, and a 258 aa cytoplasmic domain. The ECD features both an IgV and IgC domain, which is commonplace in the BTN/BTNL proteins, but the IgC domain is relatively weak (1-4). The ECD of human BTNL9 shares 66% and 67% aa sequence identity with rat and mouse, respectively. Human BTNL9 mRNA has been identified in adipose, lung, thymus, spleen, colon, and cardiac tissues, but its highest levels of expression were found in B cells (2, 5). Although the specific function of BTNL9 has yet to be fully elucidated, recombinant BTNL9-Fc has been shown to bind to many immune cells including T cells, B cell, macrophages, and dendritic cells (6). BTNL9 expression has also been found to be down-regulated in colon cancer tumors (5). R&D in house data indicate that BTNL9 protein inhibits the secretion of IFN-gamma from anti-CD3 activated PBMC.
- Arnett, H.A. et al. (2014) Nat Rev Immunol. 14:5596.
- Arnett, H.A. et al. (2009) Cytokine 46:370.
- Abeler-Dorner, L. et al. (2012) Trends Immunol. 33:34.
- Rhodes, D. et al. (2016) Annu. Rev. Immunol. 34:151.
- Lebrero-Fernandez, C. et al. (2016) Immun. Inflammation Dis. 4:191.
- Yamazaki, T. et al. (2010) J. Immunol. 185:5907.
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human BTNL9 Fc Chimera Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human BTNL9 Fc Chimera Protein, CF and earn rewards!
Have you used Recombinant Human BTNL9 Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
